FINWIRES · TerminalLIVE
FINWIRES

Kinder Morgan Sees Strong Q3 Momentum, RBC Says

By

Kinder Morgan (KMI) enters Q3 with strong momentum driven by commodity price tailwinds and operational execution, RBC Capital Markets said in an earnings preview Tuesday.

The company is expected to report Q3 results on Oct. 21.

RBC said that in addition to the Western Gateway joint venture, Kinder Morgan could add an incremental $400 million of projects to its backlog in the near term.

The investment firm said that based on the change in WTI crude prices and its 2026 WTI price forecast of around $85 per barrel, it increased the company's carbon dioxide segment earnings before depreciation, depletion, and amortization forecasts by $27 million for Q3 and $104 million in 2026.

RBC maintained its sector perform rating on the stock and raised its price target to $36 per share from $35.

Price: $31.70, Change: $-0.02, Percent Change: -0.08%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA